SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

PLoS One. 2014;9(8):e104354.

Circulating TNF receptors are significant prognostic biomarkers for idiopathic membranous nephropathy.

, , , , , , , , , ,

제1저자 이수미, 양승희 · 교신저자 이정표

소속 (8)
  1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Department of Internal Medicine, Dong-A University, Busan, Korea.
  2. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Kidney Research Institute, Seoul National University, Seoul, Korea.
  3. Department of Internal Medicine, National Medical Center, Seoul, Korea.
  4. Department of Dental Hygiene, College of Health Science, Eulji University, Seongnam, Korea.
  5. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.
  6. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
  7. Severance Biomedical Science Institute, Brain Korea 21 and Department of Internal Medicine, Yonsei University, Seoul, Korea.
  8. Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.

Abstract

Idiopathic membranous nephropathy (iMN) is a common cause of nephrotic syndrome in adults. A biomarker to accurately indicate the severity of iMN and predict long-term prognosis is insufficient. Here, we evaluated the clinical significance of circulating tumor necrosis factor receptors (cTNFRs) as prognostic biomarkers of iMN with nephrotic syndrome. A total of 113 patients with biopsy-proven iMN and 43 healthy volunteers were enrolled in this study. Ninety patients with iMN had nephrotic range proteinuria. Levels of cTNFRs were measured by using serum samples collected at the time of initial diagnosis. Levels of cTNFRs were higher in the patients with nephrotic syndrome than in those with subnephrotic range proteinuria or in the healthy volunteers (P for trend <0.001). Estimated glomerular filtration rate and proteinuria tended to worsen as the cTNFRs levels increased. Having a cTNFR1 level within the highest tertile was a significant risk factor for renal progression after adjustment, in comparison with the other tertiles (hazard ratio [HR], 3.39; 95% confidence interval [95% CI], 1.48-7.78; P = 0.004). The cTNFR2 level within the highest tertile also significantly increased the risk of renal progression (HR, 3.29; 95% CI, 1.43-7.54; P = 0.005). Renal tubular TNFRs expression was associated with cTNFRs level. However, the cTNFRs levels were not associated with autoantibody against phospholipase A2 receptor reactivity/levels or treatment response. This study demonstrated that cTNFRs levels at the time of initial diagnosis could predict renal progression in patients with iMN.

Figures

Figure 1
Figure 1 Circulating TNFRs levels in the patients with iMN compared with those in the healthy volunteers. **P<0.001, *P<0.05.
Figure 2
Figure 2 Proportion of the patients based on severity of pathological findings according to circulating TNFRs levels. (A) Correlation between the pathological findings and the circulating TNFR1 tertiles. (B) Correlation between the pathological findings and circulating TNFR2 tertiles.
Figure 3
Figure 3 Kaplan-Meier survival curves of renal progression. (A) The patients with cTNFR1 level within the highest tertile had a significantly faster renal progression compared with those with cTNFR1 level within the other tertiles (P<0.001, log-rank test). (B) The patients with cTNFR2 level within the highest tertile also had a significantly faster renal progression compared with those with cTNFR2 level within the other tertiles (P<0.001, log-rank test). (C) ROC curves for circulating TNFR1 (cTNFR1), circulating TNFR2 (cTNFR2), UPCR, and serum creatinine (sCr) determining renal progression. The AUCs for cTNFR1, cTNFR2, sCr, and UPCR were 0.719 (95% confidence interval [95% CI]: 0.597–0.841), 0.724 (95% CI: 0.599–0.849), and 0.520 (95% CI: 0.375–0.666), 0.607 (95% CI: 0.479–0.735), respectively.
Figure 4
Figure 4 Correlation between the circulating TNFRs levels and autoantibody against phospholipase A2 receptor (anti-PLA2R). (A) The statistically insignificant relationship between Ln cTNFR1 level and anti-PLA2R. (B) The statistically insignificant relationship between Ln cTNFR2 level and anti-PLA2R.
Figure 5
Figure 5 Renal expression of TNFRs according to circulating TNFRs. (A) Immunohistochemical staining of TNFRs expression in paraffin-embedded kidney biopsy sections. TNFR1 is expressed in the glomeruli and tubules in the patients with subnephrotic proteinuria, low cTNFRs levels, and high cTNFRs levels, respectively. TNFR2 is expressed in the tubules but rarely in the glomeruli in the patients with subnephrotic proteinuria, low cTNFRs levels, and high cTNFRs levels, respectively. The intensity of the TNFR2 expression was relatively weaker than that of TNFR1 expression. Original magnification, ×20. (B) Quantitative immunohistochemical analysis of renal TNFRs expression. The quantitative immunohistochemical staining value (QISV, %) was calculated as the integrated optical density divided by the total area occupied by the stained sections in each slide by using computer-assisted quantitative analysis (Qwin3, Leica, Rijswijk, Netherlands). (C) Renal expression of TNFRs in the glomeruli or tubules by performing real-time quantitative reverse transcription-polymerase chain reaction. The Kruskal-Wallis test with Dunn’s method was used. *P<0.05.

그림 출처: PubMed Central 공개 논문 (PMC4123977)

Conflict of interest statement

Competing Interests:The authors have declared that no competing interests exist.

그 밖의 정보
출판 형태
Journal Article, Research Support, Non-U.S. Gov't
저널
PloS one · eISSN 1932-6203
전자 출판
2014-08-06
MeSH
Adult · Aged · Biomarkers / blood · Female · Glomerular Filtration Rate* · Glomerulonephritis, Membranous* / blood / diagnosis / physiopathology · Humans · Male · Middle Aged · Nephrotic Syndrome* / blood / diagnosis / physiopathology · Prognosis · Receptors, Tumor Necrosis Factor, Type I / blood · Receptors, Tumor Necrosis Factor, Type II / blood
Substances
Biomarkers · Receptors, Tumor Necrosis Factor, Type I · Receptors, Tumor Necrosis Factor, Type II
참고문헌
44편